SCHEMBL8207764

SCHEMBL8207764

Cc1nc(C(C)C)c(C(C)C)c(=O)[nH]1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
GAA P10253 2/20 0.37
PARP1 P09874 4/20 0.36
TNKS2 Q9H2K2 1/20 0.36
PDE2A O00408 3/20 0.35
MAPK1 P28482 1/20 0.35
PDE3B Q13370 1/20 0.35
PDE3A Q14432 1/20 0.35
KDM5B Q9UGL1 1/20 0.34
KDM5A P29375 1/20 0.34
TRPV1 Q8NER1 2/20 0.34
KDM4E B2RXH2 1/20 0.33
NPC1 O15118 1/20 0.33
USP2 O75604 1/20 0.33
GLA P06280 1/20 0.33
MAPT P10636 1/20 0.33
HPGD P15428 1/20 0.33
RAB9A P51151 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19503077 0.81 ALDH1A1 (0.50) ALDH1A1L3MBTL1GAAPARP1TNKS2
SCHEMBL24900155 0.79 KDM4E (0.34) ALDH1A1PDE3BPDE3AKDM5BKDM4E
SCHEMBL19760867 0.78 POLB (0.47) ALDH1A1L3MBTL1GAAPARP1TNKS2
SCHEMBL8212090 0.78 PNP (0.41) ALDH1A1KDM4EGLAMAPT
SCHEMBL13693758 0.75 KDM5A (0.43) ALDH1A1L3MBTL1GAAPARP1TNKS2
SCHEMBL12338168 0.75 ALDH1A1 (0.36) ALDH1A1L3MBTL1GAAPARP1TNKS2
SCHEMBL19503753 0.72 CDK4 (0.39) ALDH1A1L3MBTL1GAAPARP1TNKS2
SCHEMBL5302407 0.70 ADORA3 (0.33) ALDH1A1
SCHEMBL11979453 0.69 SMPD3 (0.39)
SCHEMBL14491969 0.67 ALDH1A1 (0.33) ALDH1A1L3MBTL1GAAPARP1TNKS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10954251-B2 Thienopyrimidine inhibitors of atypical protein kinase C CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2021-03-23 US disclosed
US-20190106433-A1 THIENOPYRIMIDINE INHIBITORS OF ATYPICAL PROTEIN KINASE C WINDTREE THERAPEUTICS, INC. 2019-04-11 US disclosed
EP-2074106-B1 DIBENZOFURAN DERIVATIVES AS INHIBITORS OF PDE-4 AND PDE-10 MYLAN LAB LTD (IN) 2013-04-17 EP disclosed
US-8263648-B2 Diebenzofuran derivatives as inhibitors of PDE-4 and PDE-10 Mylan Laboratories Ltd. (IN) 2012-09-11 US disclosed
US-20090281131-A1 DIEBENZOFURAN DERIVATIVES AS INHIBITORS OF PDE-4 AND PDE-10 MYLAN LABORATORIES LIMITED (IN) 2009-11-12 US disclosed
WO-2009115874-A2 NOVEL HETEROCYCLIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESSES FOR THEIR PREPARATION MATRIX LABORATORIES LTD. (IN) 2009-09-24 WO disclosed
WO-2008032171-A1 DIBENZOFURAN DERIVATIVES AS INHIBITORS OF PDE-4 AND PDE-10 MATRIX LABORATORIES LTD. (DE) 2008-03-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190106433-A1 THIENOPYRIMIDINE INHIBITORS OF ATYPICAL PROTEIN KINASE C PRKX, PRKCQ, PRKACA ALDH1A1 4002/4885L3MBTL1 2788/4885GAA 2759/4885
US-10954251-B2 Thienopyrimidine inhibitors of atypical protein kinase C PRKX, PRKCQ, PRKACA ALDH1A1 4002/4885L3MBTL1 2788/4885GAA 2759/4885
US-20090281131-A1 DIEBENZOFURAN DERIVATIVES AS INHIBITORS OF PDE-4 AND PDE-10 PDE4A, PDE4B, PDE12 ALDH1A1 234/4885L3MBTL1 4154/4885GAA 261/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.